Based on these findings, we speculate that exogenous RSPO2 treatment can induce increased ERK1/2 phosphorylation in thyroid cancer cells, and that the effect of RSPO2 is strongly dependent on expression of GPR48/LGR4. The gene discussed is MAPK3; the disease is thyroid gland carcinoma.